Aprea Therapeutics Inc logo

APRE - Aprea Therapeutics Inc News Story

$4.42 -0.6  -11.1%

Last Trade - 12/04/21

Sector
Healthcare
Size
Small Cap
Market Cap £76.8m
Enterprise Value £11.9m
Revenue £n/a
Position in Universe 5145th / 6825

Aprea Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021

Fri 8th January, 2021 1:00pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210108:nGNX6K2p9j&default-theme=true


BOSTON, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq:
APRE), a biopharmaceutical company focused on developing and commercializing
novel cancer therapeutics that reactivate the mutant tumor suppressor protein,
p53, today announced that Christian S. Schade, Chairman and Chief Executive
Officer, will present a corporate update at the 39th Annual J.P. Morgan
Healthcare Conference on Tuesday, January 12, 2021 at 2:50 p.m. ET.

A live webcast of the presentation can be accessed under the "Events Calendar"
in the Investors section of the Aprea website at L
(https://www.globenewswire.com/Tracker?data=mNAYdXglSNxaEJhYQ9GdO7DMI04bZf4lXHIsF5JdbWdb0OcAwWb2HbFQXR2zrb4KSCJGd0iHNcjsJ4Lm5co5XKyuXJ-LpOgd5feBbQcksIXluuvs_rDhueF_AR9EErnvrL-iBFLOhW0oWoAAqGZkSMzfxEksWHPNhsJlnV97cgd-0kWIGw0sK0NGk7TXtb46)i
(https://www.globenewswire.com/Tracker?data=gx27Vlfso2kEsncitqmMmAsXkEhZ-YqlKfUwxTe8vHKLNLd797H1ffHMEIPScD4UwwRWI6alh7TBFHnoMeyd3tc0F-2fPwgWLHtcY3bKVVU_mZeZK8Z2aufdPI_AnofxiwzN8itGgGL_8h0pRLudrOJA3XFzHnmt0lXbcIn5Bi9ch7vchLCDVuM0JtaYVee4)nk
(https://www.globenewswire.com/Tracker?data=FBZw_GaJugD1uyhtXbL-h_xIw0CSbGCjQEJYcYFCi67Khoz-sSpN8-aMiGzcEGAXOeA3K_hWDYEAM_5W8AgADRiLldmfOTf69chNpO_siQyNsDkrH3iVsWTL4Hwx_5rf73KoeNi6CjIbI0fdEYiAHIDxdOfLV_baYh9biog1_azzO1MOeTEJxk2cgnWyy-Tl).

About Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in
Boston, Massachusetts with research facilities in Stockholm, Sweden, focused
on developing and commercializing novel cancer therapeutics that reactivate
mutant tumor suppressor protein, p53. The Company’s lead product candidate
is eprenetapopt (APR-246), a small molecule in clinical development for
hematologic malignancies and solid tumors. Eprenetapopt has received
Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA for
myelodysplastic syndromes (MDS), Fast Track designation from the FDA for acute
myeloid leukemia (AML), and Orphan Drug designation from the European
Commission for MDS and AML. APR-548, a next generation small molecule
reactivator of mutant p53, is being developed for oral administration. For
more information, please visit the company website at www.aprea.com.

The Company may use, and intends to use, its investor relations website at
https://ir.aprea.com/ as a means of disclosing material nonpublic information
and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statement

Certain information contained in this press release includes
“forward-looking statements”, within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended, related to our study analyses, clinical trials,
regulatory submissions and projected cash position. We may, in some cases use
terms such as “future,” “predicts,” “believes,” “potential,”
“continue,” “anticipates,” “estimates,” “expects,”
“plans,” “intends,” “targeting,” “confidence,” “may,”
“could,” “might,” “likely,” “will,” “should” or other
words that convey uncertainty of the future events or outcomes to identify
these forward-looking statements. Our forward-looking statements are based on
current beliefs and expectations of our management team that involve risks,
potential changes in circumstances, assumptions, and uncertainties. Any or all
of the forward-looking statements may turn out to be wrong or be affected by
inaccurate assumptions we might make or by known or unknown risks and
uncertainties. These forward looking statements are subject to risks and
uncertainties including risks related to the success and timing of our
clinical trials or other studies, risks associated with the coronavirus
pandemic and the other risks set forth in our filings with the U.S. Securities
and Exchange Commission. For all these reasons, actual results and
developments could be materially different from those expressed in or implied
by our forward-looking statements. You are cautioned not to place undue
reliance on these forward-looking statements, which are made only as of the
date of this press release. We undertake no obligation to publicly update such
forward-looking statements to reflect subsequent events or circumstances.

Source: Aprea Therapeutics, Inc.

Corporate Contacts:

Scott M. Coiante

Sr. Vice President and Chief Financial Officer

617-463-9385

Gregory A. Korbel

Vice President of Business Development

617-463-9385


(https://www.globenewswire.com/NewsRoom/AttachmentNg/4b5be207-2832-49b4-9e6a-15869e433e16)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.